КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ: КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ
Аннотация
Рак предстательной железы (РПЖ) является одной из актуальных проблем современной онкоурологии. Заболеваемость данной патологией неуклонно растет во всем мире. Несмотря на широкое использование ПСА-диагностики и введения программ, направленных на раннее выявление данного заболевания, частота диагностики запущенных форм РПЖ остается высокой. Кроме того, ряд аспектов терапии данного заболевания до настоящего момента остается спорным. С 3 по 5 октября 2012 г. в Москве состоялся VII конгресс Российского общества онкоурологов, на котором освещались некоторые вопросы комбинированного лечения местно-распространенных форм РПЖ. В статье освещен ряд спорных вопросов при проведении терапии больных РПЖ в различных клинических ситуациях.
Список литературы
1. Yossepowitch O., Eggener S.E., Bianco F.J. Jr et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007;178(2):493−9.
2. D’Amico A.V., Whittington R., Malkowicz S.B. et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17(1):168−72.
3. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937−46.
4. Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243−52.
5. Bolla M., Gonzalez D., Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337(5):295−300.
6. Hanks G.E., Lu J., Machtay M. et al. RTOG protocol 92-02: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locallyadvanced carcinoma of the prostate. Proc Am Soc Clin Oncol 2000:19:1284.
7. Ward J.F., Slezak J.M., Blute M.L. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95(6):751−6.
8. Weckermann D., Hamm M., Dorn R. et al. Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions. Urologe A 2006;45(6):723−7.
9. Klevecka V., Musch M., Roggenbuck U. et al – Extended pelvic node dissection allows better identification of lymph node metastasis in patients with clinically localized prostate cancer. J Urol 2006;175:450.
10. Heidenreich A., Von Klobloch R., Varga Z. et al. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy (RRP) – an update on > 300 cases. J Urol 2004;171:312.
11. Bader P., Burkhard F.C., Markwalder R., Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169(3):849−54.
12. Schulman C.C., Debruyne F.M., Forster G. et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38(6):706−13.
13. Soloway M.S., Pareek K., Sharifi R. et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112−6.
14. Gleave M.E., Goldenberg S.L., Chin J.L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166(2):500−6.
15. Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472−9.
16. Ghavamian R., Bergstralh E.J., Blute M.L. et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161:1223−8.
17. Dorff T.B., Flaig T.W., Tangen C.M. et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29(15):2040−5.
18. Wiegel T., Bottke D., Steiner U. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924−30.
19. Bolla M., Van Poppel H., Collette L. et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005;366:572−8.
20. Nudell D.M., Grossfeld G.D., Weinberg V.K. et al. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999;54(6):1049−57.
21. Zietman A.L., Prince E.A., Nakfoor B.M.et al. Androgen deprivation and radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38(5):1067−70.
22. Roach M. 3rd, Bae K., Speight J. et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26(4):585−91.
23. Porter A.T., Elhilali M., Manji M. et al. A phase III randomized trial to evaluate the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients. A Canadian Urologic Oncology Group study. Proc Am Soc Clin Oncol 1997;16 (Abstr. 1123).
24. Denham J.W., Steigler A., Lamb D.S. et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised cont rolled trial. Lancet Oncol 2005; 6(11):841−50.
25. Bolla M., de Reijke T.M., Van Tienhoven GEORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360(24):2516−27.
Для цитирования:
Алексеев Б.Я., Нюшко К.М. КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ: КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ. Онкоурология. 2012;8(4):77-82. https://doi.org/10.17650/1726-9776-2012-8-4-77-82
For citation:
Alekseev B.Y., Nyushko K.M. COMBINATION THERAPY FOR PROSTATE CANCER: CLINICAL OBSERVATIONS. Cancer Urology. 2012;8(4):77-82. (In Russ.) https://doi.org/10.17650/1726-9776-2012-8-4-77-82
Просмотров: 415
Послать статью по эл. почте 